There is no written testing program designed to assess the stability characteristics of drug products.
Inspection Record
People's Custom Rx and Clinical Care, LLC — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
The flow of components, drug product containers, closures, in-process materials, and drug products though the building is not designed to prevent contamination.
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.
Routine calibration of equipment is not performed according to a written program designed to assure proper perfo rmance .
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
About this record
Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
